CN101590166A - A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof - Google Patents
A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof Download PDFInfo
- Publication number
- CN101590166A CN101590166A CNA2008101132125A CN200810113212A CN101590166A CN 101590166 A CN101590166 A CN 101590166A CN A2008101132125 A CNA2008101132125 A CN A2008101132125A CN 200810113212 A CN200810113212 A CN 200810113212A CN 101590166 A CN101590166 A CN 101590166A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- medicine composition
- extract
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 29
- 210000000582 semen Anatomy 0.000 claims abstract description 16
- 239000008589 Cortex Fraxini Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- 239000006187 pill Substances 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002934 diuretic Substances 0.000 abstract description 5
- 230000001882 diuretic effect Effects 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 17
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 210000000544 articulatio talocruralis Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 206010018634 Gouty Arthritis Diseases 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 208000003899 Foreign-Body Granuloma Diseases 0.000 description 2
- 208000005422 Foreign-Body reaction Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002407 reforming Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NTDFJPCHHGBHCO-UHFFFAOYSA-N 7,9-dihydro-3H-purine-2,6,8-trione Chemical compound OC1=NC(O)=C2NC(O)=NC2=N1.N1C(=O)NC(=O)C2=C1NC(=O)N2 NTDFJPCHHGBHCO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Abstract
The invention discloses a kind of Chinese medicine composition for the treatment of gout and preparation method thereof.This Chinese medicine composition is to be prepared from according to a certain weight ratio by Rhizoma Smilacis Glabrae, Cortex Fraxini, Radix Gentianae Macrophyllae, Radix Paeoniae Rubra, Semen Plantaginis.It can be prepared to any common drug dosage form.Chinese medicine composition of the present invention has the effect of heat clearing and damp drying, detoxifcation, diuretic, easing joint movement, is used for the treatment of gout.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Gout is uric acid crystal and tissue injury's property disease of causing in purine metabolism obstacle and the blood in the body.Various disease conditions such as clinical characters is that hyperuricemia and the gouty arthritis that causes are thus shown effect repeatedly, tophus deposition, gouty kidney and dysbolismus pathological changes are shown effect for seeing with gouty arthritis repeatedly.Along with people's living standard improves, the change of nutrition and diet structure, the gout sickness rate is and obviously increases trend.
The traditional Chinese medical science thinks that the joint meridians that stagnate flow by the resistance of the turbid damp stasis of blood in gout system, and due to QI and blood was smooth, non-general ailment said due to cold or exposure was done.The heresy of turbid damp, non-be subjected in outside, and in main being born in.General patient with gout is mainly in middle-aged and elderly people, plump people, its internal organs degradation, if having a liking for the food greasy and surfeit flavour, infringement function of a specified duration is the most outstanding to damage the pure and impure metabolic function of spleen kidney especially.Dysfunction of the spleen in transportation, ascending the clear and descending the turbid is had no right, the weary gasification of kidney, separating clear and excreting turbid mistake department, water paddy is reforming not, gives birth in the turbid poison, is detained in the blood, with the capable distribution of blood, a series of pathological changes takes place.Diseases such as gouty arthritis are the marks of disease, purine metabolism obstacle (the pure and impure metabolism of spleen kidney) is not normal is only disease this, the turbid poison of uric acid is the middle pathological product of pathological changes, and produces disease such as gouty arthritis thus.
The inventor thinks that the cause of disease of gout mainly is that institute causes by " give birth in damp and hot, the turbid poison, diseases caused by retention of fluid is stagnated ", so the rule of treatment is worked as based on heat clearing and damp drying, detoxifcation, diuretic, easing joint movement.
Summary of the invention
The invention provides a kind of new Chinese medicine composition, said composition has the effect of heat clearing and damp drying, detoxifcation, diuretic, easing joint movement, is used for the treatment of gout.
Another object of the present invention provides the preparation method of above-mentioned Chinese medicine composition.
The present invention is achieved by the following technical solutions:
The present invention is made by the following weight proportion raw material: Rhizoma Smilacis Glabrae 15-60 part, Cortex Fraxini 6-12 part, Radix Gentianae Macrophyllae 3-9 part, Radix Paeoniae Rubra 6-12 part, Semen Plantaginis 9-15 part.
Preferred weight portion proportioning is: 30 parts of Rhizoma Smilacis Glabraes, 9 parts of Cortex Fraxinis, 6 parts of Radix Gentianae Macrophyllae, 9 parts of Radix Paeoniae Rubra, 12 parts of Semen Plantaginiss.
The preparation method of Chinese medicine composition of the present invention is as follows:
Above medical material adds 8 times of amount 70% ethanol extractions, extract 2 times, each 1-1.5 hour, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract, add appropriate amount of auxiliary materials, be prepared into pharmaceutically acceptable oral formulations, for example capsule, tablet, pill, drop pill etc.
The preparation method of the preferred pill of Chinese medicine composition of the present invention is as follows:
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
The preparation method of Chinese medicine composition preferred capsule of the present invention agent is as follows:
Extract is ground into fine powder, adds lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
The preparation method of the preferred tablet of Chinese medicine composition of the present invention is as follows:
Extract is ground into fine powder, adds lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
The compatibility mechanism of pharmaceutical composition of the present invention is as follows:
The traditional Chinese medical science thinks that the joint meridians that stagnate flow by the resistance of the turbid damp stasis of blood in gout system, and due to QI and blood was smooth, non-general ailment said due to cold or exposure was done.The heresy of turbid damp, non-be subjected in outside, and in main being born in.General patient with gout is mainly in middle-aged and elderly people, plump people, its internal organs degradation, if having a liking for the food greasy and surfeit flavour, infringement function of a specified duration is the most outstanding to damage the pure and impure metabolic function of spleen kidney especially.Dysfunction of the spleen in transportation, ascending the clear and descending the turbid is had no right, the weary gasification of kidney, separating clear and excreting turbid mistake department, water paddy is reforming not, gives birth in the turbid poison, is detained in the blood, with the capable distribution of blood, a series of pathological changes takes place.Diseases such as gouty arthritis are the marks of disease, purine metabolism obstacle (the pure and impure metabolism of spleen kidney) is not normal is only disease this, the turbid poison of uric acid is the middle pathological product of pathological changes, and produces disease such as gouty arthritis thus.
The inventor thinks that the cause of disease of gout mainly is that institute causes by " give birth in damp and hot, the turbid poison, diseases caused by retention of fluid is stagnated ", so the rule of treatment is worked as based on heat clearing and damp drying, detoxifcation, diuretic, easing joint movement.
In the drug composition, the mechanism of action of each medicine is as follows in the present invention:
Rhizoma Smilacis Glabrae: sweet, light, flat.Return liver, stomach warp.Dehumidifying, detoxifcation, easing joint movement.Be used for damp and hot stranguria with turbid discharge, leukorrhagia, carbuncle, the limbs contracture due to the scrofula, scabies, syphilis and mercurialism, bones and muscles pain.
Cortex Fraxini: bitter, puckery, cold.Return liver, gallbladder, large intestine channel.Heat clearing and damp drying, astringent therapy makes eye bright.Be used for hematodiarrhoea, have loose bowels, leucorrhea with red and white discharge, conjunctival congestion and swelling pain, order is given birth to the nebula film.
Radix Gentianae Macrophyllae: hot, bitter, flat.Return stomach, liver, gallbladder meridian.Wind-damp dispelling, clearing away damp-heat, stopping numbness pain.Be used for rheumatic arthralgia, the contracture of muscle arteries and veins, joint is ached, afternoon fever, infantile malnutrition heating.
Radix Paeoniae Rubra: hardship is slightly cold.Return Liver Channel.Clearing away heat and cooling blood, eliminating stasis to stop pain.Be used for maculae caused by violent heat pathogen, hematemesis and epistaxis, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea, lump in the abdomen stomachache, injury from falling down, carbuncle skin infection.
Semen Plantaginis: sweet, be slightly cold.Return liver, kidney, lung, small intestine meridian.Clearing away heat and promoting diuresis, eliminating dampness by diuresis is treating stranguria, makes eye bright, and eliminates the phlegm.Be used for the edema distension, the puckery pain of pyretic stranguria, diarrhea due to summer heat and dampness, conjunctival congestion and swelling pain, phlegm-heat cough.
In the present invention in the drug composition with Rhizoma Smilacis Glabrae as monarch drug, bring into play the effect of its dehumidifying, detoxifcation, easing joint movement, Cortex Fraxini, Radix Gentianae Macrophyllae are as ministerial drug, play the effect of heat clearing and damp drying, Radix Paeoniae Rubra, Semen Plantaginis make for assistant altogether, get the effect of its clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body, five medicines are harmonious, and play the effect of heat clearing and damp drying, detoxifcation, diuretic, easing joint movement altogether.
Below, foregoing of the present invention is described in further detail by the specific embodiment:
Concrete embodiment
Embodiment 1:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
Embodiment 2:
Rhizoma Smilacis Glabrae 20kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 40kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 3:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 12kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 40kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Embodiment 4:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 9kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
Embodiment 5:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 12kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 40kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 6:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 15kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 40kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Embodiment 7:
Rhizoma Smilacis Glabrae 15kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds proper honey, evenly mixed, the pill agent.
Embodiment 8:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 6kg, Radix Gentianae Macrophyllae 6kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 40kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 9:
Rhizoma Smilacis Glabrae 30kg, Cortex Fraxini 9kg, Radix Gentianae Macrophyllae 3kg, Radix Paeoniae Rubra 9kg, Semen Plantaginis 12kg
Above medical material adds 8 times of amount 70% ethanol extractions, extracts 2 times, and each 1 hour, being concentrated into relative density was the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract;
Extract is ground into fine powder, adds the 40kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Further set forth the beneficial effect of pharmaceutical composition of the present invention by following experiment:
The laboratory observation of traditional Chinese medicine composition for treating rat gout model of the present invention
1 materials and methods
1.1 laboratory animal and grouping
30 of Wistar cleaning level male rats, body weight 200-250g is divided into normal group, gout model group and Chinese herb prevention group at random, 10 every group.
1.2 the preparation of urate crystal
With reference to the Seemiller method, uric acid (Uric acid) is dissolved in the NaOH solution of 1mol/L, adjust pH with HCl, through stirring, filtration, cold drying, screening, sterilize, be prepared into aseptic urate crystal.
1.3 gout Preparation of model
The scorching animal model of experimental uric acid salt ankle joint is made with reference to Coderre TJ and the improvement of Chen Shi method and is carried out.With sterile working's method, with No. 4 injection needles,, inject the articulatio tibiotarsalis intracavity of gout model group and Chinese herb prevention group rat right hind leg internal malleolus with 5% urate solution, 50 μ l, each animal is only injected 1 time.
1.4 medicine
Treatment group rat is raised with Chinese medicine composition medicinal liquid of the present invention, with 10 times of amounts of per kilogram of body weight of people, 4h left and right sides gastric infusion after modeling in the preparation of gout model.Irritate stomach every day 1 time, continuously 3d.Normal group and gout model group rat are irritated isopyknic normal saline.
1.5 observation index
1.5.1 general signs
Observe the outward appearance of rat right hind leg internal malleolus articulatio tibiotarsalis, the active situation of limbs etc.
1.5.2 the K+ concentration of right side ankle joint and surrounding tissue thereof
After modeling the 4th day, the sacrificed by decapitation animal is got hot-tempered joint, right side and surrounding tissue thereof, weighs, homogenate, centrifuging and taking supernatant, with the K+ concentration of the U.S. SYNCHRON EL-ISE of Beckman company analysis-e/or determining tissue.
1.5.3 the tissue pathologies change of right side ankle joint and surrounding tissue thereof
Get right side ankle joint and surrounding tissue thereof, make light microscopic and detect.With conventional method with specimen fix, decalcification, paraffin embedding, section, HE dyeing.
2 results
2.1 general signs
Gout model group and treatment rat, after being injected urate solution about the 2nd day (about 24h), the articulatio tibiotarsalis of internal malleolus has occurred all that ankle swelling in various degree, slow, the sufficient pawl of walking are curled, limbs are reluctant to put forth effort to bear a heavy burden, and individual animal hind leg occurs and excessively bows in the wrongly, even walks lamely.After the modeling day, treatment was organized right ankle swelling and is disappeared obviously, various signs on the whole, the gout model group overweights the treatment group.
2.2 the K+ concentration of right side ankle joint and surrounding tissue thereof
The K+ concentration of gout model group ankle joint and surrounding tissue thereof is apparently higher than normal group (p＜0.05), and no tangible difference (table 1) between treatment group and the normal group.
The K+ concentration of table 1 ankle joint and surrounding tissue thereof (x ± S)
Compare * p＜0.05 with normal group
2.3 the tissue pathologies change of ankle joint and surrounding tissue thereof
Normal group: ankle joint and structures surrounding thereof are normally clear, do not have any tissue pathologies change.
The gout model group: finding during topography has the urate crystal calmness in the ankle joint intracavity.The visible down significantly arthritis pathology of light microscopic changes, there is tangible foreign body granuloma to form around the tibia shank, show as the more foreign body multinucleated giant cell of appearance in the foreign body granuloma tissue, newborn little vascularization and more fibroblast, local cartilaginous tissue is destroyed.
Treatment group: the urate crystal calmness is arranged in the ankle joint intracavity.Visible arthritis pathology changes under the light microscopic, and the foreign body multinucleated giant cell is less sees, has newborn little vascularization and the local cartilaginous tissue of less fibroblast that destruction is also arranged.But on the population structure, significantly better than the gout model group, what have has almost recovered normal.
3 these experimental results of conclusion have pointed out utilization Chinese medicine composition of the present invention to be used for the treatment of the rat acute gout model that caused by the local injection urate, can obtain comparatively satisfied effect.General signs takes a turn for the better, the PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM that the swelling of ankle joint has the K+ concentration of significantly disappear joint and surrounding tissue thereof obviously to reduce tissue also shows, the pathological change of treatment group arthritis compares with the gout model group, improves significantly on population structure.Chinese medicine composition of the present invention can effectively be treated gout.
Claims (6)
1, a kind of Chinese medicine composition that is used for the treatment of gout is characterized in that, it is to be made by following bulk drugs: Rhizoma Smilacis Glabrae 15-60 part, Cortex Fraxini 6-12 part, Radix Gentianae Macrophyllae 3-9 part, Radix Paeoniae Rubra 6-12 part, Semen Plantaginis 9-15 part.
According to the Chinese medicine composition of claim 1, it is characterized in that 2, it is to be made by following bulk drugs: 30 parts of Rhizoma Smilacis Glabraes, 9 parts of Cortex Fraxinis, 6 parts of Radix Gentianae Macrophyllae, 9 parts of Radix Paeoniae Rubra, 12 parts of Semen Plantaginiss.
3, the preparation method of claim 1 or 2 described Chinese medicine compositions, it is characterized in that, this method is: above medical material adds 8 times of amount 70% ethanol extractions, extracts each 1-1.5 hour 2 times, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get extract, add appropriate amount of auxiliary materials, be prepared into capsule, tablet, pill, drop pill.
4, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of pill is: extract is ground into fine powder, adds proper honey, and evenly mixed, the pill agent.
5, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of capsule is: extract is ground into fine powder, adds lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
6, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of tablet is: extract is ground into fine powder, adds lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101132125A CN101590166B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101132125A CN101590166B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101590166A true CN101590166A (en) | 2009-12-02 |
| CN101590166B CN101590166B (en) | 2012-08-08 |
Family
ID=41405166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101132125A Active CN101590166B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590166B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850063A (en) * | 2010-04-02 | 2010-10-06 | 贵阳春科药业技术研发有限公司 | Medicinal preparation for preventing and treating gout and preparation method |
| CN108653538A (en) * | 2018-07-17 | 2018-10-16 | 李开国 | A kind of Chinese herbal medicine formula for treating gout |
| CN110251564A (en) * | 2019-07-11 | 2019-09-20 | 青岛大学 | A kind of externally applied drug and preparation method thereof for treating gouty arthritis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286502C (en) * | 2004-08-26 | 2006-11-29 | 成都中汇制药有限公司 | Medicine for treating gout affection and its symptoms |
| CN100531769C (en) * | 2006-09-05 | 2009-08-26 | 广州固志医药科技有限公司 | Chinese medicine composition for treating gout and preparing method thereof |
-
2008
- 2008-05-27 CN CN2008101132125A patent/CN101590166B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850063A (en) * | 2010-04-02 | 2010-10-06 | 贵阳春科药业技术研发有限公司 | Medicinal preparation for preventing and treating gout and preparation method |
| CN108653538A (en) * | 2018-07-17 | 2018-10-16 | 李开国 | A kind of Chinese herbal medicine formula for treating gout |
| CN110251564A (en) * | 2019-07-11 | 2019-09-20 | 青岛大学 | A kind of externally applied drug and preparation method thereof for treating gouty arthritis |
| CN110251564B (en) * | 2019-07-11 | 2021-06-29 | 青岛大学 | External medicine for treating gouty arthritis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101590166B (en) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN100443112C (en) | Medicine for treating gout and gout arthritis | |
| CN101062372A (en) | Chinese herbal medicine preparation for dissolving hepatobiliary system calculi | |
| CN100355450C (en) | Qinchuan Tongbi tablet | |
| CN106266463B (en) | Traditional Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590169B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590166B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101112533A (en) | Chinese traditional medicine composition for treating and preventing gout and method of making the same | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN102038778A (en) | Chinese medicinal composition with effects of relaxing meridians, activating collaterals, expelling wind and removing dampness and preparation method thereof | |
| CN104721313B (en) | A kind of care drug for the treatment of acute lumbar injury | |
| CN104107288A (en) | Sinew-relaxing collateral-activating pill | |
| CN106362066A (en) | Medicinal liquor for treatment of rheumatic and rheumatoid diseases and preparation method thereof | |
| CN106166262A (en) | A kind of Chinese medicine composition treating chronic renal failure | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN100427132C (en) | Traditional Chinese medicine for treating rheumatism and its preparing process | |
| CN109758559A (en) | A kind of Chinese medicine composition and its preparation method and application for treating chronic fatigue syndrome | |
| CN103893436B (en) | A kind of externally applied drug for treating rheumatism | |
| CN1083269C (en) | Chinese herbal medicine for treating hysteromyoma and breast fibrosarcoma and its prepn. method | |
| CN114984160B (en) | Mongolian medicine for treating alcoholic liver disease | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN102631496B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN107982409B (en) | Traditional Chinese medicine composition and pill for treating syringomyelia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP03 | Change of name, title or address |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee after: Beijing Increasepharm Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180904 Address after: 519000 room 312-60, 3 / F, aviation and new town planning exhibition hall, Jin Wan District, Zhuhai, Guangdong (central office area) Patentee after: Ying Kerui (Zhuhai) innovation Pharmaceutical Manufacturing Co.,Ltd. Address before: 102299 Beijing 6 Changping District science and Technology Park No. 79, No. 24, No. Patentee before: Beijing Increasepharm Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: 519090 No. 201, 2nd Floor, South Side of Plant 3#, No. 362, Dingwan 7th Road, Sanzao Town, Jinwan District, Zhuhai City, Guangdong Province Patentee after: Yingkerui (Zhuhai Jinwan) Pharmaceutical Co.,Ltd. Address before: 519000 room 312-60, 3 / F, aviation and new town planning exhibition hall, Jin Wan District, Zhuhai, Guangdong (central office area) Patentee before: Ying Kerui (Zhuhai) innovation Pharmaceutical Manufacturing Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230103 Address after: 102299 Room 408 and 409, Floor 4, Building 24, No. 79 Yard, Shuangying West Road, Science Park, Changping District, Beijing Patentee after: Beijing Baode Runsheng Health Management Co.,Ltd. Address before: 519090 No. 201, 2nd Floor, South Side of Plant 3#, No. 362, Dingwan 7th Road, Sanzao Town, Jinwan District, Zhuhai City, Guangdong Province Patentee before: Yingkerui (Zhuhai Jinwan) Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |